期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 118, 期 12, 页码 4002-4013出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI36663
关键词
-
资金
- NIH [R37 NS34467, R37 AG023084, R37 AG13956]
Neurotoxic amyloid beta peptide (A beta) accumulates in the brains of individuals with Alzheimer disease (AD). The APOE4 allele is a major risk factor for sporadic AD and has been associated with increased brain parenchymal and vascular amyloid burden. How apoE isoforms influence A beta accumulation in the brain has, however, remained unclear. Here, we have shown that apoE disrupts A beta clearance across the mouse blood-brain barrier (BBB) in an isoform-specific manner (specifically, apoE4 had a greater disruptive effect than either apoE3 or apoE2). A beta binding to apoE4 redirected the rapid clearance of free A beta 40/42 from the LDL receptor-related protein 1 (LRP1) to the VLDL receptor (VLDLR), which internalized apoE4 and A beta-apoE4 complexes at the BBB more slowly than LRP1. In contrast, apoE2 and apoE3 as well as A beta-apoE2 and A beta-apoE3 complexes were cleared at the BBB via both VLDLR and LRP1 at a substantially faster rate than A beta-apoE4 complexes. Astrocyte-secreted lipo-apoE2, lipo-apoE3, and lipo-apoE4 as well as their complexes with A beta were cleared at the BBB by mechanisms similar to those of their respective lipid-poor isoforms but at 2- to 3-fold slower rates. Thus, apoE isoforms differentially regulate A beta clearance from the brain, and this might contribute to the effects of APOE genotype on the disease process in both individuals with AD and animal models of AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据